Favipiravir

Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan.

Uses your system voice; voice and rate in settings.

≈ 5 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections, including SARS-CoV-2. Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative.

It is being developed and manufactured by Toyama Chemical (a subsidiary of Fujifilm) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensed it to Zhejiang Hisun Pharmaceutical Co. It became a generic drug in 2019.

Medical use

Favipiravir has been approved to treat influenza in Japan. It is, however, only indicated for novel influenza (strains that cause more severe disease) rather than seasonal influenza. As of 2020, the probability of resistance developing appears low.

Side effects

There is evidence that use during pregnancy may result in harm to the baby. Teratogenic and embryotoxic effects were shown on four animal species. In one case report, a 6-month old infant developed benign bright blue discolouration of the cornea after treatment with favipiravir which resolved after treatment cessation.

Mechanism of action

The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase. Favipiravir is a prodrug that is metabolized to its active form, favipiravir-ribofuranosyl-5'-triphosphate (favipiravir-RTP), available in both oral and intravenous formulations. In 2014, favipiravir was approved in Japan for stockpiling against influenza pandemics.

However, favipiravir has not been shown to be effective in primary human airway cells, casting doubt on its efficacy in influenza treatment. Favipiravir-RTP is a nucleoside analogue. It mimics both guanosine and adenosine nucleobases for viral RNA dependant RNA polymerase (RdRp).

Incorporating two favipiravir ribofuranosyl bases in a row stops extension of the newly made RNA, although it is unclear how as of 2013.

Synthesis

Multiple methods have been developed to synthesize favipiravir.

Use in Russia

Coronavir is the brand name of favipiravir used in Russia, where it is approved for the treatment of COVID-19. It is produced and sold by R-Pharm. Coronavir was approved for use in Russia in hospitals in July 2020, and in September 2020 it received approval for prescription sales for outpatient use. Avifavir, another drug also based on favipiravir, was earlier approved in May.

COVID-19

Favipiravir, as an antiviral drug, has been authorized for treating COVID-19 in several countries including Japan, Russia, Serbia, Turkey, India, and Thailand, under emergency provisions. A rapid meta-review in September 2020 (analyzing four studies) noted that the drug led to clinical and radiological improvements; however, no reduction in mortality or differences in oxygen-support requirement were observed and more rigorous studies were sought.

A Cochrane Systematic review published in Feb 20241, noted that there is actually no real benefit with Favipiravir in treating Covid-19 in terms of mortality benefits, or admission to mechanical ventillation, or hospitalisation, and it may not make any difference in adverse effects or serious adverse effects.

Ebola

Research in 2014, suggested that favipiravir may have efficacy against Ebola based on studies in mouse models; efficacy in humans was unaddressed. During the 2014 West Africa Ebola virus outbreak, a French nurse who contracted Ebola while volunteering for Médecins Sans Frontières (MSF) in Liberia reportedly recovered after receiving a course of favipiravir.

A clinical trial investigating the use of favipiravir against Ebola virus disease began in Guéckédou, Guinea, in December 2014. Preliminary results presented in 2016 at the Conference on Retroviruses and Opportunistic Infections (CROI), later published, showed a decrease in mortality in patients with low-to-moderate levels of virus in blood, but no effect on patients with high levels (the group at a higher risk of death).

The trial design was concomitantly criticised for using only historical controls.

Hantavirus

Favipiravir shows efficacy against hantavirus in animal models and has seen some limited trials in humans.

Other

In experiments in animals favipiravir has shown activity against West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Activity against enteroviruses and Rift Valley fever virus has also been demonstrated.

Favipiravir has showed limited efficacy against Zika virus in animal studies, but was less effective than other antivirals such as MK-608. The agent has also shown some efficacy in rabies, and has been used experimentally in some humans infected with the virus.

Tautomerism

The possible tautomerism of favipiravir has been investigated computationally and experimentally. It was found that the enol-like form was substantially more stable in organic solvents than the keto-like form, meaning that Favipiravir likely exists almost exclusively in the enol-like form.

In aqueous solution the keto-like tautomer is substantially stabilized due to the specific interaction with the water molecules. Upon protonation the keto form is switched on.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378495858 under CC BY-SA 4.0; modifications have been made.

Words in each sectionEbolaEbolaEbola: 133 words133Mechanism of actionMechanism of actionMechanism of action: 117 words117COVID-19COVID-19COVID-19: 110 words110TautomerismTautomerismTautomerism: 87 words87OtherOtherOther: 81 words81Use in RussiaUse in RussiaUse in Russia: 63 words63Side effectsSide effectsSide effects: 49 words49Medical useMedical useMedical use: 37 words37HantavirusHantavirusHantavirus: 16 words16SynthesisSynthesisSynthesis: 8 words8
Words in each section. Measured from the stored article body; sections below the minimum are not plotted.

References

  1. ↩Wikipedia “Favipiravir” revision 1378495858 · retrieved 2026-10-20 publication date (×1) · confidence 0.95 revision URL

Provenance

snapshot enwiki-001378495858 · captured 2026-10-04 · ledger · version history

Cite this page as: encyclopegia.org, “Favipiravir”, snapshot enwiki-001378495858. https://encyclopegia.org/a/favipiravir